paraoxon has been researched along with Chronic Illness in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bar-Klein, G; Biala, Y; Daninos, M; Friedman, A; Kamintsky, L; Kassirer, M; Krivoy, A; Lavon, O; Makarovsky, I; Ramaty, E; Rosman, Y; Shrot, S; Statlender, L; Yaari, Y | 1 |
| Bełtowski, J; Jamroz, A; Wójcicka, G | 1 |
2 other study(ies) available for paraoxon and Chronic Illness
| Article | Year |
|---|---|
Prevention of organophosphate-induced chronic epilepsy by early benzodiazepine treatment.
Topics: Animals; Antidotes; Atropine; Cholinesterase Inhibitors; Cholinesterase Reactivators; Chronic Disease; Epilepsy; Midazolam; Muscarinic Agonists; Obidoxime Chloride; Paraoxon; Pesticides; Pilocarpine; Rats; Rats, Sprague-Dawley; Status Epilepticus | 2014 |
Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Animals; Antimetabolites, Antineoplastic; Antioxidants; Aryldialkylphosphatase; Biomarkers; Cholinesterase Inhibitors; Chronic Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperlipidemias; Isoprostanes; Lactones; Leptin; Male; Models, Cardiovascular; Oxidative Stress; Paraoxon; Phenylacetates; Rats; Rats, Wistar; Statistics as Topic | 2003 |